8-K: Coeptis Faces Nasdaq Delisting Warning Over Annual Meeting

Coeptis Therapeutics Holdings, Inc. received a Nasdaq delisting notice for failing to hold its annual shareholder meeting, but plans to regain compliance by January 30, 2026.

Summary

• Coeptis Therapeutics Holdings, Inc. received a letter from the Nasdaq Listing Qualifications Department on January 12, 2026.
• The letter indicated a violation of Nasdaq Listing Rules 5620(a) and 5810(c)(2)G) due to the company's failure to hold an annual meeting of shareholders within twelve months of its fiscal year end of December 31, 2024.
• Nasdaq rules require the company to submit a plan to regain compliance within 45 calendar days from January 12, 2026.
• If Nasdaq accepts the plan, an exception of up to 180 calendar days from the fiscal year end, or until June 29, 2026, may be granted to regain compliance.
• The company has scheduled an annual meeting of shareholders for January 30, 2026, as previously disclosed in its Form S-4 dated January 5, 2026.
• Management believes this scheduled meeting will be sufficient to permit the company to regain compliance with the Annual Meeting Rule.

Sentiment

Score: 3

Explanation: The filing indicates a significant corporate governance failure (failure to hold an annual meeting) leading to a Nasdaq delisting warning. While the company has a plan to address it, the initial non-compliance is a negative event that raises concerns about operational execution and regulatory adherence. The forward-looking statement about regaining compliance is positive, but the underlying issue is serious.

Positives

• The company has a clear, stated plan to address the non-compliance by scheduling an annual meeting on January 30, 2026.
• Management expresses belief that the scheduled meeting will be sufficient to regain compliance with Nasdaq's listing rules.

Negatives

• Received a formal notice from Nasdaq regarding non-compliance with Listing Rules 5620(a) and 5810(c)(2)G).
• Failed to hold an annual meeting of shareholders within the required twelve months of the December 31, 2024 fiscal year end.

Risks

• Failure to submit an acceptable plan to Nasdaq within 45 calendar days from January 12, 2026, could lead to further delisting proceedings.
• Even if a plan is accepted, failure to successfully hold the annual meeting and regain compliance by June 29, 2026 (the maximum exception period) could result in delisting.
• Forward-looking statements regarding the ability to regain compliance are not guarantees and are subject to various known and unknown risks and uncertainties that could cause actual results to vary materially.

Future Outlook

The company anticipates regaining compliance with Nasdaq's listing rules by holding its annual meeting on January 30, 2026. This expectation is a forward-looking statement and is subject to various risks and uncertainties.

Management Comments

• The company is currently scheduled to hold an annual meeting of shareholders on January 30, 2026, which the company believes will be sufficient to permit it to regain compliance with the Annual Meeting Rule.

Industry Context

This event underscores the critical importance of adhering to fundamental corporate governance requirements for publicly traded companies. Nasdaq's enforcement of its listing rules, particularly regarding shareholder meetings, is standard practice across major exchanges to ensure transparency and accountability. Companies, especially those in the often-volatile biotechnology sector, must maintain rigorous administrative and governance practices to avoid such compliance issues that can erode investor confidence and potentially impact market access.

Comparison to Industry Standards

• Nasdaq Listing Rule 5620(a) mandates that listed companies hold an annual meeting of shareholders no later than one year after the end of the company's fiscal year. This is a widely accepted corporate governance standard across global stock exchanges, including the NYSE and major European and Asian markets, designed to ensure regular accountability of management to shareholders.
• Failure to comply, as seen with Coeptis, is a deviation from standard industry practice and can trigger formal delisting procedures. Other companies facing similar issues typically respond by promptly scheduling the overdue meeting and submitting a detailed compliance plan to the exchange, often within the initial 45-day window provided by Nasdaq.
• The company's proactive scheduling of the annual meeting for January 30, 2026, aligns with the typical response strategy observed in comparable situations where companies aim to quickly rectify the non-compliance to mitigate further regulatory action and investor concern.

Corporate Governance

Stakeholder Impact

• Shareholders: Face uncertainty regarding the company's continued listing on Nasdaq, potential impact on share liquidity and price, and delayed opportunity to exercise voting rights at an annual meeting.
• Investors: May view the non-compliance as a governance red flag, potentially impacting investment decisions and the company's valuation.
• Regulatory Authorities: Nasdaq has issued a formal notice, indicating their oversight and the potential for further action if compliance is not regained.

Next Steps

• Submit a plan to Nasdaq to regain compliance within 45 calendar days from January 12, 2026.
• Hold the annual meeting of shareholders on January 30, 2026.
• Regain compliance with Nasdaq Listing Rules by June 29, 2026, if an exception is granted.

Key Dates

Recommendation

The company has received a serious delisting warning from Nasdaq due to a failure in corporate governance (not holding an annual meeting). While management has a plan to rectify this by scheduling a meeting on January 30, 2026, and expresses confidence in regaining compliance, the situation introduces significant uncertainty and risk. Investors should hold to see if the company successfully executes its plan and regains compliance, as failure to do so could lead to delisting and a substantial negative impact on share price. A 'sell' would be premature given the stated plan, but a 'buy' is not warranted until the compliance issue is fully resolved.

Keywords

Coeptis Therapeutics, Nasdaq, Delisting, Listing Rules, Annual Meeting, Corporate Governance, Compliance, COEP